Daily Anesthesiology Research Analysis
Three impactful anesthesiology-related studies stood out today: a mechanistic discovery linking nociceptor Npr2/cGMP signaling to heat and TRPV1-mediated pain, a randomized non-inferiority trial showing ciprofol-remifentanil provides stable sedation for flexible bronchoscopy with better hemodynamics than propofol, and a double-blind RCT indicating erector spinae plane block is not superior to systemic lidocaine for thoracotomy analgesia. Together, they span basic pain biology and pragmatic perio
Summary
Three impactful anesthesiology-related studies stood out today: a mechanistic discovery linking nociceptor Npr2/cGMP signaling to heat and TRPV1-mediated pain, a randomized non-inferiority trial showing ciprofol-remifentanil provides stable sedation for flexible bronchoscopy with better hemodynamics than propofol, and a double-blind RCT indicating erector spinae plane block is not superior to systemic lidocaine for thoracotomy analgesia. Together, they span basic pain biology and pragmatic perioperative decision-making.
Research Themes
- Nociceptor cGMP signaling and pain mechanisms
- Optimizing procedural sedation with new IV anesthetics (ciprofol)
- Regional anesthesia versus systemic analgesia after thoracotomy
Selected Articles
1. Nociceptor-specific signaling of the receptor guanylyl cyclase Npr2 contributes to acute and persistent pain.
Using nociceptor-specific Npr2 deletion in adult mice, the authors show that cGMP signaling via Npr2 is required for normal heat nociception and TRPV1-mediated pain behaviors and calcium responses. The study positions Npr2 as a key upstream modulator of acute and persistent pain processing in primary sensory neurons.
Impact: This work uncovers a nociceptor-intrinsic cGMP pathway that modulates TRPV1-linked pain, highlighting Npr2 as a mechanistically validated analgesic target.
Clinical Implications: While preclinical, targeting Npr2-cGMP signaling could yield non-opioid analgesics for heat and inflammatory pain states relevant to perioperative pain management.
Key Findings
- Npr2 is highly expressed in nociceptors and drives cGMP production relevant to pain processing.
- Nociceptor-specific Npr2 deletion impairs noxious heat sensing and reduces TRPV1-mediated nocifensive behaviors.
- Calcium responses associated with TRPV1 activation are diminished in Npr2-deficient mice, implicating Npr2 upstream of TRPV1 signaling.
Methodological Strengths
- Cell type–specific genetic deletion in adult nociceptors isolates the role of Npr2.
- Convergent behavioral and cellular (Ca2+) readouts strengthen mechanistic inference.
Limitations
- Preclinical mouse model limits direct clinical generalizability.
- Abstracted data are truncated; detailed quantitative effect sizes are not available in the provided text.
Future Directions: Validate Npr2-TRPV1 coupling across pain modalities and species, and develop selective Npr2 modulators to test analgesic efficacy in translational models.
Natriuretic peptide receptor 2 (Npr2; also termed guanylyl cyclase B) is a transmembrane guanylyl cyclase that is highly abundant in nociceptors. Here, we investigated the role of production of cyclic GMP (cGMP) by Npr2 in pain processing. Adult mice with a deletion of Npr2 specifically in nociceptive sensory neurons exhibited deficits in noxious heat sensing, which can activate the nonselective cation channels TRPV1 and TRPA1. In parallel, Npr2-deficient mice showed a reduction in TRPV1-mediated nocifensive behavior and Ca
2. Enhanced hemodynamic stability and patient satisfaction with ciprofol-remifentanil versus propofol-remifentanil for sedation in shorter-duration fiberoptic bronchoscopy: a prospective, randomized, double-blind study.
In a double-blind non-inferiority RCT of 209 FOB patients, ciprofol-remifentanil achieved similar procedural success to propofol-remifentanil while providing better hemodynamic stability, less injection pain, and higher satisfaction. Findings support ciprofol as a viable alternative sedative for short bronchoscopy procedures.
Impact: Head-to-head randomized evidence for a newer IV anesthetic (ciprofol) demonstrates practical advantages over propofol in a common procedural sedation setting.
Clinical Implications: Ciprofol may improve hemodynamic stability and patient experience during FOB without compromising procedural success; adoption would require local training, formulary inclusion, and broader validation across procedures and populations.
Key Findings
- Non-inferior procedural completion: 92.45% with ciprofol-remifentanil vs 90.57% with propofol-remifentanil.
- Greater hemodynamic stability with ciprofol-based sedation compared with propofol.
- Reduced injection pain and higher patient satisfaction in the ciprofol group.
Methodological Strengths
- Prospective randomized double-blind non-inferiority design with trial registration.
- Adequate sample size (n=209) for primary outcome and safety signals.
Limitations
- Details on dosing regimens and full hemodynamic metrics are not provided in the abstract text.
- Single procedure context (FOB) limits generalizability to longer or higher-risk procedures.
Future Directions: Conduct multicenter trials across varied procedures (e.g., endoscopy, interventional pulmonology), benchmark recovery profiles, airway reflex suppression, and cost-effectiveness, and evaluate high-risk subgroups.
OBJECTIVE: This study aimed to compare the efficacy and safety of ciprofol-remifentanil versus propofol-remifentanil in patients undergoing fiberoptic bronchoscopy (FOB). METHODS: In this prospective, randomized, double-blind, non-inferiority trial, 209 patients undergoing FOB were enrolled and equally divided into two groups ( RESULTS: The successful completion rate of FOB was 92.45% (98 of 106) in the ciprofol-remifentanil group and 90.57% (96 of 106) in the propofol-remifentanil group ( CONCLUSION: Ciprofol-remifentanil was non-inferior to propofol-remifentanil in terms of sedation during fiberoptic bronchoscopy;. Furthermore, ciprofol-remifentanil was associated with greater hemodynamic stability, reduced pain on injection, and higher satisfaction scores, suggesting that it may be a preferable alternative to propofol-remifentanil for FOB procedures. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/, ChiCTR2400081603.
3. The erector spinae plane block is not superior to perioperative systemic lidocaine infusion for postoperative analgesia management after thoracotomy: a randomized double-blind study.
In a three-arm randomized double-blind trial after major thoracotomy, ESP block and IV lidocaine both modestly improved early pain scores versus placebo, but ESP block did not reduce 24-h opioid consumption compared with systemic lidocaine. Absolute opioid differences versus standard care were small (3–4.5 mg morphine).
Impact: Provides pragmatic randomized evidence that a simpler systemic analgesic (IV lidocaine) performs comparably to a popular fascial plane block for thoracotomy, informing resource-conscious postoperative pain strategies.
Clinical Implications: For thoracotomy analgesia pathways, systemic lidocaine infusion may offer similar opioid-sparing benefits to ESP block with less procedural complexity; focus may shift to patient selection, safety monitoring, and multimodal combinations.
Key Findings
- ESPB and IV lidocaine lowered early postoperative VAS versus placebo but had minimal absolute impact on cumulative opioids over 24 h.
- No superiority of ESPB over systemic lidocaine in 24-h morphine consumption (30.25±5.1 vs 28.7±3.1 mg; p=0.567).
- Rescue analgesia need was reduced in both ESPB and lidocaine groups versus placebo, with no difference between ESPB and lidocaine.
Methodological Strengths
- Randomized double-blind three-arm design including an active comparator and placebo.
- Clinically relevant endpoints (opioid consumption, pain scores, rescue analgesia).
Limitations
- Sample size and power calculations are not specified in the abstract, limiting interpretation of equivalence.
- Effect sizes were small; study may be underpowered to detect modest differences in opioid use.
Future Directions: Larger multicenter RCTs to compare ESPB with systemic lidocaine and other regional techniques on longer-term outcomes (pulmonary complications, chronic post-thoracotomy pain), and cost-effectiveness analyses.
BACKGROUND: The effect of erector spinae plane block and systemic lidocaine infusion for major thoracotomy is still unclear. Therefore, we aimed to compare ESPB, systemic lidocaine and standard analgesia in patients who undergoing major thoracotomy. METHODS: Patients with ASA I-III, aged between 18 and 65 years scheduled for major thoracotomy were enrolled. Patients were randomly assigned to receive an intravenous (IV) infusion of placebo combined with ESP block using placebo (group P), ESP block with 0.25% bupivacaine combined with IV placebo (group ESPB), or IV-lidocaine combined with ESP-block using placebo (group L). The primary outcome was postoperative (24 h) total opioid consumption. The secondary outcomes were VAS scores, rescue analgesia, and intraoperative remifentanil consumption. RESULTS: Resting VAS scores were significantly lower in both groups ESPB and L compared to group P during the first four postoperative hours. Similarly, dynamic VAS scores were lower in group ESPB and group L compared to group P during the first two postoperative hours (p < 0.05). ESP block was not found to be superior to systemic lidocaine in reducing morphine requirements during the first 24 h (30.25 ± 5.1 vs. 28.7 ± 3.1 respectively, p = 0.567). Additionally, the difference in morphine consumption between group P and either ESP-block or systemic lidocaine groups was minimal, amounting to only 3-4.5 mg. However, the requirement for rescue analgesia was significantly lower in both groups ESPB and L compared to group P (p < 0.05). There was no difference between groups ESPB and L in terms of rescue analgesia requirement. CONCLUSION: ESP block did not demonstrate superior postoperative analgesic efficacy compared to systemic lidocaine in patients undergoing major thoracotomy.